These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38036719)

  • 41. Identification of a competing endogenous RNA network related to immune signature in clear cell renal cell carcinoma.
    Zhang Y; Dai J; Huang W; Chen Q; Chen W; He Q; Chen F; Zhang P
    Aging (Albany NY); 2021 Dec; 13(24):25980-26002. PubMed ID: 34958632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and Validation of a Nine-Redox-Related Long Noncoding RNA Signature in Renal Clear Cell Carcinoma.
    Qi-Dong X; Yang X; Lu JL; Liu CQ; Sun JX; Li C; Wang SG
    Oxid Med Cell Longev; 2020; 2020():6634247. PubMed ID: 33425212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Risk Signature with Autophagy-Related Long Noncoding RNAs for Predicting the Prognosis of Clear Cell Renal Cell Carcinoma: Based on the TCGA Database and Bioinformatics.
    Xuan Y; Chen W; Liu K; Gao Y; Zuo S; Wang B; Ma X; Zhang X
    Dis Markers; 2021; 2021():8849977. PubMed ID: 34040677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Risk Score Model Based on Nine Differentially Methylated mRNAs for Predicting Prognosis of Patients with Clear Cell Renal Cell Carcinoma.
    Zhou J; Liu G; Wu X; Zhou Z; Li J; Ji Z
    Dis Markers; 2021; 2021():8863799. PubMed ID: 33510822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
    Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
    Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.
    Liu W; Qu C; Wang X
    Oncol Res; 2023; 31(4):543-567. PubMed ID: 37415739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
    Bao W; Han Q; Guan X; Wang Z; Gu M
    Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.
    Peng L; Liang J; Wang Q; Chen G
    Front Genet; 2022; 13():798846. PubMed ID: 35656315
    [No Abstract]   [Full Text] [Related]  

  • 50. A novel oxidative-stress related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma.
    Zhang Y; Zhou G; Shi W; Shi W; Hu M; Kong D; Long R; Chen N
    Sci Rep; 2023 Apr; 13(1):5740. PubMed ID: 37029263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas.
    Yao J; Chen Y; Wang Y; Liu S; Yuan X; Pan F; Geng P
    Int J Clin Exp Pathol; 2014; 7(6):2758-67. PubMed ID: 25031695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ferroptosis-Related Long Noncoding RNA Signature Predicts Prognosis of Clear Cell Renal Carcinoma.
    Liu JW; Supandi F; Dhillon SK
    Folia Biol (Praha); 2022; 68(1):1-15. PubMed ID: 36201853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LncRNA ITGB2-AS1 promotes the progression of clear cell renal cell carcinoma by modulating miR-328-5p/HMGA1 axis.
    Zhang W; Lu Y; Shi H; Li X; Zhang Z; Deng X; Yang Y; Wan B
    Hum Cell; 2021 Sep; 34(5):1545-1557. PubMed ID: 34170494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.
    Chen X; Tu J; Ma L; Huang Y; Yang C; Yuan X
    Int J Gen Med; 2022; 15():3215-3235. PubMed ID: 35342303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Down-regulation of long noncoding RNA PGM5-AS1 correlates with tumor progression and predicts poor prognosis in clear cell renal cell carcinoma.
    Qian M; Zheng JL; Kang N; Su YL
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10685-10690. PubMed ID: 31858536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis.
    Zhou Y; Zhang Z; Wo M; Xu W
    Bioengineered; 2021 Dec; 12(1):8994-9005. PubMed ID: 34643163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel necroptosis-related lncRNAs signature for survival prediction in clear cell renal cell carcinoma.
    Zhao L; Luo H; Dong X; Zeng Z; Zhang J; Yi Y; Lin C
    Medicine (Baltimore); 2022 Sep; 101(39):e30621. PubMed ID: 36181033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.